Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled,
parallel-group study, followed by an OLE, is designed to evaluate the safety,
tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD.
LRRK2-PD is defined as ...
Age: 30 years - 66+
Gender: All
A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
In this study, researchers will learn more about a study drug called BIIB122 in participants
with early-stage Parkinson's disease (PD). The study will focus on participants with a
specific genetic variant in their LRRK2 gene.
The main question researchers are tr...
Age: 30 - 80 years
Gender: All
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational,
multi-center natural history study to assess progression of clinical features, digital
outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD)
progression in ...
Age: 30 years - 66+
Gender: All
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first
in-human study that will evaluate the safety of intracisternal LY3884961 administration
in patients with moderate to severe Parkinson's disease with at least 1 pathogenic GBA1
mutation....
Age: 35 - 80 years
Gender: All
A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless).
This is a multi-center, randomized, double blind, active controlled clinical Study. Following
a screening period, eligible subjects will be enrolled to an open-label oral IR LD/CD
adjustment period; then an open-label ND0612 conversion period; then after optimizatio...
Age: 30 - 80 years
Gender: All
Nilotinib in Parkinson's Disease
This study will assess the safety and tolerability of daily oral administration of nilotinib
(150-300mg once daily) in Parkinson's Disease.
Age: 40 - 79 years
Gender: All